In light of the low CSF exposures and lack of effects on dopamine metabolites, we concluded that the plausibility of observing changes in proteinopathy biomarkers in the CSF, such as α-synuclein, phospho-α-synuclein, or phospho-tau, is too low to warrant additional analyses, although the biospecimens are available for future studies. This evidence concerns the gene MAPT and proteostasis deficiencies.